Suppr超能文献

HDAC5 的催化活性可抑制心肌细胞氧化应激和 NRF2 靶基因表达。

HDAC5 catalytic activity suppresses cardiomyocyte oxidative stress and NRF2 target gene expression.

机构信息

Department of Medicine, Division of Cardiology and Consortium for Fibrosis Research & Translation, University of Colorado Anschutz Medical Campus, Aurora, Colorado 80045.

Department of Molecular Cardiology and Epigenetics, Heidelberg University, Heidelberg, Germany; German Centre for Cardiovascular Research, Heidelberg/Mannheim, Germany.

出版信息

J Biol Chem. 2019 May 24;294(21):8640-8652. doi: 10.1074/jbc.RA118.007006. Epub 2019 Apr 8.

Abstract

Histone deacetylase 5 (HDAC5) and HDAC9 are class IIa HDACs that function as signal-responsive repressors of the epigenetic program for pathological cardiomyocyte hypertrophy. The conserved deacetylase domains of HDAC5 and HDAC9 are not required for inhibition of cardiac hypertrophy. Thus, the biological function of class IIa HDAC catalytic activity in the heart remains unknown. Here we demonstrate that catalytic activity of HDAC5, but not HDAC9, suppresses mitochondrial reactive oxygen species generation and subsequent induction of NF-E2-related factor 2 (NRF2)-dependent antioxidant gene expression in cardiomyocytes. Treatment of cardiomyocytes with TMP195 or TMP269, which are selective class IIa HDAC inhibitors, or shRNA-mediated knockdown of HDAC5 but not HDAC9 leads to stimulation of NRF2-mediated transcription in a reactive oxygen species-dependent manner. Conversely, ectopic expression of catalytically active HDAC5 decreases cardiomyocyte oxidative stress and represses NRF2 activation. These findings establish a role of the catalytic domain of HDAC5 in the control of cardiomyocyte redox homeostasis and define TMP195 and TMP269 as a novel class of NRF2 activators that function by suppressing the enzymatic activity of an epigenetic regulator.

摘要

组蛋白去乙酰化酶 5(HDAC5)和 HDAC9 是 IIa 类组蛋白去乙酰化酶,作为病理性心肌细胞肥大的表观遗传程序的信号反应抑制剂发挥作用。HDAC5 和 HDAC9 的保守去乙酰化酶结构域对于抑制心肌肥大不是必需的。因此,心脏中 IIa 类组蛋白去乙酰化酶催化活性的生物学功能仍然未知。在这里,我们证明了 HDAC5 的催化活性,但不是 HDAC9 的催化活性,可抑制心肌细胞中活性氧物种的生成,并随后诱导核因子 E2 相关因子 2(NRF2)依赖性抗氧化基因表达。用 TMP195 或 TMP269(选择性 IIa 类组蛋白去乙酰化酶抑制剂)处理心肌细胞,或用 shRNA 介导的 HDAC5 而不是 HDAC9 的敲低,以依赖活性氧的方式刺激 NRF2 介导的转录。相反,催化活性的 HDAC5 的异位表达可降低心肌细胞的氧化应激并抑制 NRF2 的激活。这些发现确立了 HDAC5 的催化结构域在控制心肌细胞氧化还原稳态中的作用,并将 TMP195 和 TMP269 定义为一类新型的 NRF2 激活剂,其通过抑制表观遗传调节剂的酶活性来发挥作用。

相似文献

引用本文的文献

本文引用的文献

2
Mitochondrial Therapies in Heart Failure.心力衰竭的线粒体疗法
Handb Exp Pharmacol. 2017;243:491-514. doi: 10.1007/164_2016_123.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验